Friday, August 21, 2026 Never miss a recall or a rule change Go Pro · $20/mo →
Inside MedSpa
FDA Recall & Compliance Alerts for Medspa Owners
Devices & TechSisram Medical H1 2026: APAC Growth Offsets Margin PressuretodayComplianceWarning: Unauthorized Injectables Seized in Canada3 days agoBusiness & M&AAbbVie Files Material Event on Allergan AestheticsyesterdayInjectablesGalderma Wins EU Nod for Restylane Shaype3 days agoRegulatoryAEON Releases Expanded Data on ABP-450 Botox BiosimilaryesterdayBusiness & M&AAllergan Adds Quarterly Botox Rebate for Growth3 days agoRegulatoryNumeco Wins Panama Approval for Newlux Botulinum ToxinyesterdayBusiness & M&AAllergan Refreshes Partner Privileges Loyalty2 days agoDevices & TechSofwave Surpasses One Million Treatments WorldwideyesterdayDevices & TechUltherapy PRIME Clears FDA for Knee Skin2 days agoInjectablesDaxxify Duration Claims vs. Reality2 days agoBusiness & M&AEvolus Posts Third Straight Profitable Quarter2 days ago
1 free article left this week. A free account gets you 4 a week.Go Pro →
Devices & Tech

Sisram Medical H1 2026: APAC Growth Offsets Margin Pressure

The energy-device maker posts solid interim results as Asia-Pacific expansion compensates for Western margin compression.

Image: Inside MedSpa
1-YEAR MOVE
+3% −14%
INMD ▲1.0%
1-year price move by ticker
TickerCompany1-year change
INMDInMode Ltd.+1.0%

Sisram Medical reported H1 2026 results showing strong growth in Asia-Pacific markets, offsetting margin pressure in mature Western geographies. The company's device portfolio—including Alma Lasers (diode, alexandrite, Nd:YAG, and RF platforms) and Cutera (Xeo, Secret Pro, Prolite)—continues to drive revenue, though profitability has compressed as competitive pricing and market saturation weigh on gross margins.

APAC growth offsets margin pressure in mature Western markets.

Sisram's geographic pivot toward APAC reflects broader industry dynamics: Western markets are consolidating around a handful of device leaders (InMode, Cutera, Alma), while emerging markets in Asia offer higher growth rates and less price competition. For practice owners in North America and Europe, Sisram's margin pressure is a cautionary signal—device economics are tightening, and practices must optimize utilization and pricing to maintain ROI. Sisram's ability to sustain growth through geographic diversification will determine whether it remains a credible alternative to InMode and Cutera or becomes a regional player.

Source: original report ↗

Free alerts

Free: recall & rule-change alerts for your practice.

Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $20/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Share

https://insidemedspa.com/article/sisram-medical-h1-2026-apac-growth/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Inside MedSpa Pro

    By the time it's news, it's too late.

    The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

    Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.
    The twice-a-week intelligence brief Go Pro · $20/mo